Latest Issuance Significantly Strengthens Pinnacle’s Exclusivity Protections
News provided by Pinnacle Spine Group, LLC
DALLAS, July 12, 2017 /PRNewswire/ Pinnacle Spine Group, LLC, the pioneer of in-situ graft delivery technology, today announced that the company has been granted a U.S. patent that meaningfully reinforces its exclusivity position with respect to its in situ graft delivery technology. Patent No. 9,649,203, titled Methods of Post-Filling an Intervertebral Implant, like previously issued patents of the company, relates to the delivery of graft material to fill the internal chamber(s) of a spinal fusion device, while allowing for graft material to be in flush contact with the endplate surfaces of the adjacent vertebral bodies.
Pinnacle Spine Group pioneered and commercialized the novel concept of delivering bone graft material in situ into an implanted device in order to fill the biologic void that remains with other spinal fusion systems. This latest patent follows the receipt of three earlier U.S. patents covering Pinnacle Spine’s innovative InFill® fusion technology. The company also owns several non-U.S. applications, including applications in Australia, Canada and Europe.
“Years ago, we identified a problem with traditional interbody fusion systems – that a biologic void remained between an implant and its two adjacent vertebrae,” says Zach Sowell, President of Pinnacle Spine Group. “We developed a highly effective solution and are thrilled to now have even stronger patent protection related to in situ graft delivery directly to an implant, a technique whose value is being recognized and appreciated by the spinal fusion industry. This recognition is a testament to the technology’s usefulness and benefits, and we look forward to working with companies that are interested in adopting and using implant designs that require delivery of bone graft material in situ.”
Pinnacle Spine’s InFill® Fusion Systems include an array of innovative interbody fusion devices engineered for easier insertion, reduced subsidence through maximum contact with the apophyseal ring, a generous bone grafting area, and compatibility with the InFill® graft delivery system. The backbone of the technology is predicated on controlled and precise in-situ placement of bone graft material directly into the implanted device, to achieve maximum contact with the adjacent vertebral endplates.
For more information on Pinnacle Spine Group’s unparalleled innovation, or to become a part of the Pinnacle team, please visit www.PinnacleSpineGroup.com, or contact us at email@example.com.
About Pinnacle Spine Group, LLC
Based in Dallas, Texas, Pinnacle Spine Group, LLC is a privately held medical device company that develops and markets innovative technologies to improve spinal fusion procedures. The Company’s family of FDA-approved InFill® Fusion systems provides for superior endplate-to-endplate contact of bone graft material and a complete fill of the disc space, achieved by post-filling the implants after they have been delivered into a targeted intervertebral disc space.